Showing 1 - 10 of 22
Theory indicates that internally-differentiated professional partnerships can promote matching between heterogeneous consumers and professionals, particularly when consumers have imperfect information or markets have barriers to referrals between firms. We test this in obstetrics markets,...
Persistent link: https://www.econbiz.de/10005830274
Economic theory indicates that firms can match workers to jobs and promote productivity-enhancing specialization better than markets, yet few data exist. We empirically test whether firms enhance matching and specialization in the context of obstetrics. We then examine whether consumers benefit...
Persistent link: https://www.econbiz.de/10008751848
Persistent link: https://www.econbiz.de/10009238295
"Professional partnerships might facilitate matching between specialized professionals and heterogeneous consumers, particularly where matching across firms is limited by information, incentives or regulation. We examine the extent to which internally-differentiated medical groups promote...
Persistent link: https://www.econbiz.de/10003725603
Persistent link: https://www.econbiz.de/10008072347
Theory indicates that internally-differentiated professional partnerships can promote matching between heterogeneous consumers and professionals, particularly when consumers have imperfect information or markets have barriers to referrals between firms. We test this in obstetrics markets,...
Persistent link: https://www.econbiz.de/10012464576
Persistent link: https://www.econbiz.de/10008720512
We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with "cocktail" regimens that combine two or more drugs. Firms cannot price discriminate because each drug is produced by a different firm and a physician creates the...
Persistent link: https://www.econbiz.de/10008533391
The average price of treating a colorectal cancer patient with chemotherapy increased from about $100 in 1993 to $36,000 in 2005, due largely to the approval and widespread use of five new drugs between 1996 and 2004. We examine whether the substantial increase in spending has been worth it....
Persistent link: https://www.econbiz.de/10005061551
Persistent link: https://www.econbiz.de/10011946947